Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
2003 1
2005 1
2006 3
2007 1
2008 3
2009 1
2011 2
2012 4
2013 2
2014 2
2015 1
2016 3
2017 3
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed for Bookshelf ID: 4857510

28 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Orkin C, et al. Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6. Lancet HIV. 2018. PMID: 28993180 Clinical Trial.
Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, Petlo C, Lockman S, Makhema J, Shapiro RL. Zash R, et al. JAMA Pediatr. 2017 Oct 2;171(10):e172222. doi: 10.1001/jamapediatrics.2017.2222. Epub 2017 Oct 2. JAMA Pediatr. 2017. PMID: 28783807 Free PMC article.
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
Squillace N, Ricci E, Quirino T, Gori A, Bandera A, Carenzi L, De Socio GV, Orofino G, Martinelli C, Madeddu G, Rusconi S, Maggi P, Celesia BM, Cordier L, Vichi F, Calza L, Falasca K, Di Biagio A, Pellicanò GF, Bonfanti P; CISAI Study Group. Squillace N, et al. PLoS One. 2017 Jun 20;12(6):e0179254. doi: 10.1371/journal.pone.0179254. eCollection 2017. PLoS One. 2017. PMID: 28632758 Free PMC article.
Odefsey--another NNRTI combination for HIV.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2016 May 9;58(1494):60-1. Med Lett Drugs Ther. 2016. PMID: 27148923 No abstract available.
Genvoya--a new 4-drug combination for HIV.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2016 Feb 15;58(1488):19-21. Med Lett Drugs Ther. 2016. PMID: 26859659 No abstract available.
Drugs for HIV infection.
[No authors listed] [No authors listed] Treat Guidel Med Lett. 2014 Feb;12(138):7-16; quiz following 16. Treat Guidel Med Lett. 2014. PMID: 24457549 No abstract available.
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, Gallant JE, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J; GS-US-236-0102 Study Team. Zolopa A, et al. J Acquir Immune Defic Syndr. 2013 May 1;63(1):96-100. doi: 10.1097/QAI.0b013e318289545c. J Acquir Immune Defic Syndr. 2013. PMID: 23392460 Clinical Trial.
28 results